The Food and Drug Administration Friday authorized for emergency use two batches of drug substance manufactured for the Janssen (Johnson & Johnson) COVID-19 vaccine at an Emergent BioSolutions facility in Baltimore. After reviewing facility records and results of quality testing performed by the manufacturer, the agency said it found several other batches were not suitable for use. It continues to review additional batches and will inform the public as those reviews are completed. 

“While the FDA is not yet ready to include the Emergent BioSolutions plant in the Janssen EUA as an authorized manufacturing facility, the agency continues to work through issues there with Janssen and Emergent BioSolutions management,” the agency said.
 

Related News Articles

Headline
All clinicians should get vaccinated against COVID-19, encourage their staff and patients to get vaccinated, and recommend immunocompromised patients continue…
Headline
The AHA, America’s Essential Hospitals, Association of American Medical Colleges, Catholic Health Association of the United States, and Children’s Hospital…
Headline
The Centers for Disease Control and Prevention today adjusted its guidance for fully vaccinated individuals, urging indoor masking in states that are labeled…
Headline
The Health Resources and Services Administration today awarded 127 organizations a total of $121 million in American Rescue Plan Act funds to work with…
Headline
The Food and Drug Administration last week issued an emergency use authorization to Becton, Dickinson and Company for its sodium citrate blood specimen…
Headline
The Federal Emergency Management Agency Friday released an advisory on reimbursable communications and outreach expenses for nonprofit medical facilities and…